Curated News
By: NewsRamp Editorial Staff
August 09, 2024
Clene Featured in BioMedWire Podcast, CEO Discusses Novel Approach to Treating Neurodegenerative Diseases
Discuss on Reddit
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) is pioneering a unique approach to treat neurodegenerative diseases, potentially giving them an advantage in the biopharmaceutical market.
- Clene's CNM-Au8(R) therapy improves the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway.
- Clene's novel approach to treating neurodegenerative diseases could potentially improve the quality of life for patients and increase their rates of survival.
- Clene CEO Rob Etherington discusses the company's mission and unique approach to treating diseases in the latest episode of the BioMedWire Podcast.
Impact - Why it Matters
This news matters as it highlights a unique approach to treating neurodegenerative diseases such as ALS and MS, potentially improving survival rates for patients. The company’s focus on improving mitochondrial health and protecting neuronal function has significant implications for the treatment of these devastating diseases.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in the latest episode of the BioMedWire Podcast. Clene CEO Rob Etherington discusses the company’s mission and its unique approach to treating neurodegenerative diseases such as ALS and MS. Etherington highlights the use of an oral suspension as a novel treatment, enabling increased rates of survival for patients.
To view the podcast, visit https://ibn.fm/a7e9u. For the full press release, visit https://ibn.fm/KGwBG
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Featured in BioMedWire Podcast, CEO Discusses Novel Approach to Treating Neurodegenerative Diseases
